Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Conditions
Recurrent Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal Cancer · Recurrent Endometrial Cancer · Endometrial Cancer · Low-grade Serous Ovarian Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama_6th Ave, Birmingham, Alabama, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber / Harvard Cancer Center, Boston, Massachusetts, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Ohio State University Wexner Medical Center James Comprehensive Cancer Center, Hilliard, Ohio, United States
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Prince of Wales Hospital, Randwick, New South Wales, Australia
Peter MacCallum Cancer Center, Melbourne, Australia
Universitair Ziekenhuis Antwerpen, Edegem, Antwerp, Belgium
Grand Hopital de Charleroi, Charleroi, Hainaut, Belgium
UZLeuven, Leuven, Vlaams-Brabant, Belgium
Hopital Lyon Sud, Pierre-Bénite, Auvergne-Rhône, France
Centre Georges Francois Leclerc, Dijon, Bourgogne-Franche-Comté, France
Institut Bergonie, Bordeaux, New Aquitaine, France
Centre Francois Baclesse (CFB), Caen, Normandy, France
Centre Antoine Lacassagne, Nice, Provence Alpes Cote dAzur, France
Institut Gustave Roussy, Villejuif, Île-de-France Region, France
Rambam Health Care Campus, Haifa, Israel
Sharet Institute of Oncology, Jerusalem, Israel
Sheba Medical Center, Tel Litwinsky, Israel
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio, Italy
Humanitas S. Pio X, Milan, Italy
Istituto Europeo di Oncologia, Milan, Italy
Instituto Nazionale Tumori- Fondazione Pascale, Naples, Italy
Radboudumc, Nijmegen, Gelderland, Netherlands
Erasmus MC, Rotterdam, South Holland, Netherlands
University Medical Center Groningen, Groningen, Netherlands
Yonsei University Health System, Seoul, South Korea
Asan Medical Center, Univ. of Ulsan, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea
Korea University Guro Hospital, Seoul, South Korea
Seoul National University Hospital, Seoul, South Korea
Clinica Universidad de Navarra, Pamplona, Navarre, Spain
Institut Catala dOncologia Badalona, Badalona, Spain
Hospital Universitari Vall d'Hebron, Barcelona, Spain
Institut Catala d'Oncologia, Barcelona, Spain
Clinica Universidad Navarra (CUN) Madrid, Madrid, Spain
Fundacion Jimenez Diaz, Madrid, Spain
Hospital Universitario San Carlos, Madrid, Spain
Hospital Clinico Universitatio Santiago de Compostela, Santiago de Compostela, Spain
University of Oxford, Oxford, Oxfordshire, United Kingdom
Royal Marsden Hospital - Sutton, Sutton, Surrey, United Kingdom
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
University College London Hospitals, London, United Kingdom
Guys Hospital, London, United Kingdom
Imperial College Healthcare NHS Trust, London, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom
Study leads
Clinical Trial Management
Study Director
Regeneron Pharmaceuticals